TRAW - Traws Pharma, Inc.

1.6
-0.080   -5.000%

Share volume: 33,124
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$1.68
-0.08
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
46%
Profitability 53%
Dept financing 35%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.23%
1 Month
-18.37%
3 Months
-25.93%
6 Months
-13.98%
1 Year
-41.18%
2 Year
-90.39%
Key data
Stock price
$1.60
P/E Ratio 
0.00
DAY RANGE
$1.59 - $1.73
EPS 
-$3.15
52 WEEK RANGE
$0.97 - $3.26
52 WEEK CHANGE
-$43.46
MARKET CAP 
13.068 M
YIELD 
N/A
SHARES OUTSTANDING 
13.474 K
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$40,948
AVERAGE 30 VOLUME 
$128,777
Company detail
CEO: Steven M. Fruchtman
Region: US
Website: www.trawspharma.com
Employees: 17
IPO year: 2013
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Recent news